Regeneron Pharmaceuticals Reports $4.29 Billion Revenue in Q2 2026, Driven by Collaboration Growth

Regeneron Pharmaceuticals, Inc. reported a total revenue of $4.29 billion for the second quarter of 2026, marking a 16.7% increase from $3.68 billion in the same period of 2025. The company's net income for the quarter was $1.30 billion, or $12.23 per diluted share, compared to $1.39 billion, or $12.81 per diluted share, in the prior year. For the first half of 2026, Regeneron achieved revenues of $7.90 billion, up from $6.70 billion in the first half of 2025, while net income decreased to $2.02 billion from $2.20 billion year-over-year.

The increase in revenue was primarily driven by a significant rise in collaboration revenue, particularly from its partnership with Sanofi, which contributed $2.17 billion in the second quarter, up from $1.44 billion in the same quarter of 2025. This growth was attributed to higher sales volumes of Dupixent and other products. However, net product sales of EYLEA, which totaled $1.01 billion in the second quarter, decreased compared to $1.15 billion in the previous year, reflecting competitive pressures and a transition of patients to EYLEA HD, which saw increased sales of $596.3 million.

Regeneron has made strategic advancements, including the launch of new products and collaborations. The company is actively working on expanding its product portfolio, with several candidates in late-stage clinical trials. Notably, the company has entered into agreements with the U.S. government to provide certain products at prices benchmarked against other developed countries, which may impact future revenue streams. Additionally, Regeneron has authorized a $3 billion share repurchase program, with $2.53 billion remaining available for repurchases as of June 30, 2026.

Operationally, Regeneron reported an increase in research and development expenses, which rose to $1.63 billion in the second quarter, up from $1.42 billion in the same period last year. This increase reflects ongoing investments in clinical trials and product development. The company also reported a headcount increase, contributing to higher selling, general, and administrative expenses, which totaled $662.1 million for the quarter. As of June 30, 2026, Regeneron had cash and cash equivalents of $2.46 billion, down from $3.12 billion at the end of 2025, indicating a focus on investment in growth and development.

Looking ahead, Regeneron anticipates continued revenue growth driven by its expanding product portfolio and collaborations. However, the company faces challenges from competitive pressures in the market, particularly for EYLEA, and the potential impact of regulatory changes. Management remains optimistic about the future, emphasizing the importance of ongoing research and development efforts to sustain long-term growth and profitability.